Financial Report: Bristol-Myers Squibb 3Q08

Bristol-Myers Squibb

3Q Revenues: $5.3 billion (+14%)

3Q Earnings: $2.6 billion (earnings were $858 million in 3Q07)

YTD Revenues: $15.3 billion (+17%)

YTD Earnings: $4.0 billion (+74%)

Comments: Pharmaceutical sales were up 15% to $4.5 billion in the quarter. Growth was driven by strong performance from Plavix, Abilify, the HIV and hepatitis portfolio, as well as Orencia. Plavix sales were $1.4 billion in the quarter (+15%). Abilify sales were $564 million (+34%). Sustiva Franchise sales were $294 million (+24%). Reyataz sales were $342 million (+25%). Orencia sales were up 98% to $119 million. Avapro/Avalide sales were $334 million (+8%). Baraclude sales were up 100% to $144 million. Earnings include a $2.0 billion after-tax gain attributed to the sale of the company’s ConvaTec business. R&D expenses were up 4% to $834 million in the quarter.